GALT vs. CDTX, CYRX, OLMA, ARCT, ITOS, PHAT, ATYR, TRDA, CGC, and IMMP
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Cidara Therapeutics (CDTX), Cryoport (CYRX), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), iTeos Therapeutics (ITOS), Phathom Pharmaceuticals (PHAT), Atyr PHARMA (ATYR), Entrada Therapeutics (TRDA), Canopy Growth (CGC), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
Galectin Therapeutics vs.
Galectin Therapeutics (NASDAQ:GALT) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, Cidara Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Cidara Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.00 beat Cidara Therapeutics' score of 0.84 indicating that Galectin Therapeutics is being referred to more favorably in the media.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 50.1% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 759.38%. Cidara Therapeutics has a consensus price target of $41.71, indicating a potential upside of 58.91%. Given Galectin Therapeutics' higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Cidara Therapeutics.
Galectin Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Galectin Therapeutics' return on equity of 0.00% beat Cidara Therapeutics' return on equity.
Cidara Therapeutics received 113 more outperform votes than Galectin Therapeutics when rated by MarketBeat users. Likewise, 70.34% of users gave Cidara Therapeutics an outperform vote while only 59.01% of users gave Galectin Therapeutics an outperform vote.
Galectin Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Cidara Therapeutics has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cidara Therapeutics beats Galectin Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GALT) was last updated on 5/22/2025 by MarketBeat.com Staff
